Sanofi’s (NASDAQ:SNY) multiple sclerosis (MS) drug candidate tolebrutinib did not meet the primary endpoint of two studies ...

Recent investigations on the chemical structure of two vitamins, namely, vitamin B 1 and riboflavin, have shown that in these substances we are also dealing with pyrimidine derivatives.

Metabolic rewiring is essential for osteoclast differentiation and bone resorption. This study shows that glutaminolysis ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

Market research firm Future Market Insights projects a total of US$ 150.3 million to be generated by the serine amino acid ...

It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response ...

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...

Financing is being led by new investor AMR Action Fund with strong participation from new investor ICG Life Sciences and existing investors MANCHESTER, United Kingdom, Sept. 12, 2024 (GLOBE NEWSWIRE) ...

The drug candidate is a small molecule which is formulated as a capsule and is administered through the oral route. The drug candidate is a pyrimidine-based multi-kinase inhibitor that targets JAK2, ...

Aubagio is a pyrimidine synthesis inhibitor FDA-approved to treat relapsing forms of MS. Genzyme Corporation, a Sanofi company, manufactures the drug. The studies did not meet the primary endpoint of ...

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...